logo-loader
viewFrontier IP Group PLC

Frontier IP portfolio firm Exscientia enters drug discovery collaboration with SRI International

The agreement will see Escientia and SRI implement a new approach to drug discovery using automated synthetic-chemistry and AI

Frontier IP Group PLC - Frontier IP’s Exscientia enters drug discovery collaboration with SRI International

Frontier IP Group PLC (LON:FIPP) said its portfolio firm Exscientia has entered into a collaboration with US research centre SRI International to expedite the discovery of molecules for a high value oncology target.

The IP investor said the agreement will see the two firms implement a new approach to drug discovery using SRI’s automated synthetic-chemistry system with Exscientia's Centaur Chemist system.

READ: Frontier IP says portfolio firm Molendotech raises funds to accelerate development of bacteria tests

Exscientia uses artificial intelligence (AI) to design molecule compounds that can then be used to accelerate drug discovery.

"The opportunity to apply AI drug design through our Centaur Chemist system with SynFini automated chemistry offers an exciting opportunity to accelerate drug discovery timelines through scientific innovation and automation", Exscientia chief executive Andrew Hopkins said in a statement.

Frontier IP owns a 2.3% stake in Exscientia.

Quick facts: Frontier IP Group PLC

Price: 58.1 GBX

AIM:FIPP
Market: AIM
Market Cap: £29.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Frontier IP Group teams up with University of Cambridge to tackle gum disease

Frontier IP Group PLC's (LON:FIPP) Neil Crabb discusses with Proactive London's Andrew Scott a new joint project between themselves and the University of Cambridge to tackle gum disease. The study's received a £52,891 grant from the National Biofilms Innovation Centre (NBIC). The...

2 weeks ago

2 min read